Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody,mepolizumab |
| |
Authors: | Isao Suzaki Yurika Kimura Akihiko Tanaka Kojiro Hirano Atsushi Ishibashi Tomomi Mizuyoshi Izumi Ando Tatsuya Kitajima So Watanabe Yasuyuki Hinohira Hitome Kobayashi |
| |
Institution: | 1. Department of Otorhinolaryngology, School of Medicine, Showa University, Tokyo, Japan;2. Tokyo Metropolitan Health and Medical Treatment Corporation, Ebara Hospital, Tokyo, Japan;3. Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University, School of Medicine, Tokyo, Japan;4. Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan;5. Kamio Memorial Hospital, Tokyo, Japan |
| |
Abstract: | Eosinophilic otitis media (EOM), which is characterized by the accumulation of eosinophils in middle ear effusion and the middle ear mucosa, is a refractory type of otitis media that is often associated with asthma. Although an early diagnosis and appropriate treatment are necessary to prevent the progression of hearing loss in patients with EOM, there are currently no well-established treatments for this condition. We treated a 60-year-old male patient with asthma and EOM. The patient’s asthma was poorly controlled, despite the use of high-dose inhaled corticosteroids, long-acting beta-agonist treatment, and the regular use of systemic corticosteroids. Mepolizumab, an anti-IL-5 monoclonal antibody, was started to treat the patient’s refractory asthma. At 4 months after the initiation of mepolizumab treatment, the patient’s asthma, hearing, and middle ear effusion improved. The present case suggests that mepolizumab therapy can control EOM and asthma. |
| |
Keywords: | ACT asthma control test ACQ asthma control questionnaire ANCAs antineutrophil cytoplasmic antibodies BMI body mass index CT computed tomography EGPA eosinophilic granulomatosis with polyangiitis EOM eosinophilic otitis media FeNO exhaled nitric oxide ICS inhaled corticosteroids ILC2s group 2 innate lymphoid cells LABA long-acting beta-agonist MEE middle ear effusion Asthma Eosinophilic otitis media IL-5 Mepolizumab |
本文献已被 ScienceDirect 等数据库收录! |
|